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Introduction
The blood-brain barrier (BBB) presents a major hurdle to the delivery of drugs to the central nervous system (CNS). The capillary endothelium of the BBB is among the most restrictive barriers with tight junctions that preclude paracellular distribution, as well as efflux transporters that effectively limit transcellular passage of more permeable xenobiotics. To enable brain uptake of essential polar nutrients, highly specialized uptake systems are expressed at the BBB for example for glucose and amino acids. While the role of efflux transporters in protecting the brain from exposure to potential toxins is well appreciated, the involvement of BBB uptake transporters in brain penetration of drugs is poorly understood. Human OATP1A2 (rodent Oatp1a4) has emerged as a potentially important BBB uptake transporter for drugs (Urquhart and Kim, 2009 ). An indication of the potential of OATP1A2 as a brain drug delivery target comes from studies with statins that are OATP substrates and demonstrate neuroprotection in hypoxia and inflammatory disorders, including multiple sclerosis (Ciurleo et al., 2014; Sierra et al., 2011) . OATP1A2 (SLCO1A2) is a member of the sodium-independent uptake transporter family that was initially reported exclusively expressed at human brain microvessels and not detected in astrocytes or neurons (Gao et al., 2000; Lee et al., 2005) . It was later confirmed to be expressed on luminal membrane of BBB in tumorous and healthy adjacent tissue (Bronger et al., 2005) , although a more recent paper reports expression in neurons as well (Gao et al., 2014) . OATP1A2 transports amphipathic substrates, including bile salts, thyroid hormones, steroid conjugates, organic dyes and anionic oligopeptides, as well as xenobiotics (Franke et al., 2009 ). The substrate spectrum of OATP1A2 includes neuroactive substrates (i.e., opioid analgesic peptides), drugs with CNS side effects (e.g. the antibacterial levofloxacin that may cause seizures, toxic psychoses, increased intracranial pressure and CNS stimulation), and/or toxicities (e.g. This article has not been copyedited and formatted. The final version may differ from this version. methotrexate may cause mild white-matter changes or severe CNS demyelination and encephalopathy) (Badagnani et al., 2006; Gao et al., 2000; Maeda et al., 2007) . There is no rodent orthologue reported for OATP1A2. Oatp1a4 and Oatp1c1 are two major isoforms expressed and enriched at mouse BBB (Cheng et al., 2005; Mayerl et al., 2012) . The closest counterpart to OATP1A2 is Oatp1a4 (Slco1a4), which shares 72% gene homology. Unlike OATP1A2, Oapt1a4 is expressed at both the apical and basolateral membranes of the microvascular endothelium of the BBB (Gao et al., 1999; Ose et al., 2010) . Oatp1a4 has a wide substrate spectrum that includes amphipathic organic anions such as 17β-estradiol-17β-Dglucuronide (E 2 17βG) and statins (Kikuchi et al., 2004) , prostaglandin E1 (Taogoshi et al., 2005) and morphine-6-glucuronide (Bourasset et al., 2003) . Oatp1a4 functional expression at the rat BBB increases with pain and correlates with taurocholate transport across the BBB (Ronaldson et al., 2011 ). An earlier study from our laboratory showed that marketed triptans were substrates for OATP1A2 using BacMam2-OATP1A2 transduced HEK293 system, likely contributing to their ability to traverse the BBB (Cheng et al., 2012) . We later confirmed naratriptan to be an OATP1A2 substrate as well (K m 13.7 µM), using the same OATP1A2 expressing HEK293 system (data not published). Understanding the difference in expression of these two transporters at the BBB could improve predictions of CNS permeability of drug candidates.
Discovery-stage studies to assess CNS uptake potential are typically conducted in vitro using MDCK cells transfected with human P-gp, and in vivo in rodents to quantify brain distribution, as species difference in terms of P-gp substrate specificity and expression are minimal (Feng et al., 2008; Uchida et al., 2011b) . Using in vitro human P-gp and rodent in vivo data for evaluating the CNS penetration potential of discovery compounds with >1% brain free fraction, we found cases where compounds with low P-gp efflux activity were not taken up into rodent brain, while This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on April 23, 2015 as DOI: 10.1124 at ASPET Journals on October 13, 2017 dmd.aspetjournals.org Downloaded from DMD # 64170 6 some P-gp and/or BCRP substrates were detected at appreciable concentrations. While the former could be due to additional efflux transporters (e.g. MRP4, MRP5), the latter is most likely due to the presence of BBB uptake transporter(s) or low fraction of P-gp and/or BCRP contribution relative to passive permeability in preventing the CNS entry of the compounds (Hsiao and Unadkat, 2014) . In this study, we have focused on OATP1A2 to evaluate the potential for this uptake transporter as a target for enhancing transcellular permeability in vitro. We have established novel methodologies using the BacMam virus and quantitatively characterized the role OATP1A2 transporter plays in uptake of its substrates in both wild-type and P-gp transfected cells.
DMD # 64170
8 standard conditions with a 12-h reverse dark/light cycle. Food and water were available ad libitum.
Male C57BL/6J mice and Oatp1a4 (−/−) mice (10-18 weeks) weighing approximately 25-35 g were used for the experiments. Under pentobarbital anesthesia (30 mg/kg), the jugular vein was cannulated with polyethylene-10 catheter for the administration of drugs. The mice then received a constant intravenous infusion of sumatriptan, naratriptan, or zolmitriptan at a rate of 0.335, 0.288 and 0.313 µmol/h/kg, respectively. These compounds were dissoved in saline. Blood samples were collected from jugular vein at 30 and 60 min after treatment and brain and liver were excised immediately after blood collection at 60 min. Plasma specimens were obtained by centrifugation of the blood samples (10,000g). The plasma, brain, and liver concentrations of sumatriptan, naratriptan, and zolmitriptan were determined using LC-MS/MS analysis.
Determination of Cellular Uptake of Triptans Using a Stable Transfectant of mOatp1a4 in
HEK293 Cells
Construction of the stable transfectant of Oatp1a4 in HEK293 cells was as described previously (Ose et al., 2010) . Uptake was initiated by addition of the triptans to the incubation buffer after cells had been washed twice and preincubated at 37 o C for 10 min in Krebs-Henseleit buffer.
Uptake was terminated at a specified time by addition of buffer at 4 o C, and cells were washed three times. The amount of triptans associated with the cells and medium was determined by LC-MS/MS analysis. The protein concentrations in aliquots of cell lysate were determined using Lowry's method. Triptan uptake was assessed from the cell-to-medium ligand concentration ratio, calculated as the concentration of triptans associated with the cells divided by that in the medium.
Construction of OATP1A2 Expressing MDCKII-WT or MDCKII-MDR1 Cells
This article has not been copyedited and formatted. The final version may differ from this version. Generation of recombinant BacMam2-OATP1A2 baculovirus (second generation of BacMam vector) was described previously (Cheng et al., 2012) . Polarized Madin-Darby canine kidney (MDCKII-WT or MDCKII-MDR1) cells were used for the in vitro transport studies and were obtained from The Netherlands Cancer Institute (Amsterdam, The Netherlands). Cell cultures and transport studies were conducted according to the procedure described previously (Rautio et al., 2006) . BacMam2-OATP1A2 at an appropriate multiplicity of infection (MOI) was administered to the apical side of 24-well Transwell inserts (Millipore, Bedford, MA) 24 h post MDCKII cell seeding. The Transwell insert had a surface area of 0.33 cm 2 as specified by manufacturer. The cells were cultured for another 48 h before transport experiments.
Transport Studies across BacMam2-OATP1A2 Transduced or Non-transduced MDCKII-WT or MDCKII-MDR1 Cells
On the day of transport experiments, donor solutions were prepared by diluting test compounds in transport medium (Dulbecco's Modified Eagle Medium supplemented with 4500 mg/L Dglucose, L-glutamine, 25 mM HEPES but without sodium pyruvate and phenol red, pH 7.4).
Receiver solution was the transport medium. The transport of test compounds was measured in both directions [apical to basolateral (A→B) and basolateral to apical (B→A)]. Lucifer yellow was used as a paracellular marker to determine the integrity of MDCKII monolayer and its concentration was measured using a SpectraMax Gemini cytofluorimeter (Molecular Devices, CA) set to an excitation wavelength of 430 nm and an emission wavelength of 540 nm. The permeability at pH 7.4 (P exact ) for test compounds across MDCKII monolayer was determined by the method described previously (Tran et al., 2004) .
Membrane Localization of OATP1A2 in BacMam2-OATP1A2 Transduced MDCKII-
MDR1 Monolayers by Immunocytochemical Staining
This article has not been copyedited and formatted. The final version may differ from this version. 
Protein Quantification of OATP1A2 by LC-MS/MS
Protein quantification of OATP1A2 in OATP1A2 transduced MDCKII membrane extracts was conducted by mass spectrometry-based targeted proteomics using validated LC-MS/MS methods. Briefly, the cells were isolated from the transwell filters using the extraction buffer I of ProteoExtract membrane extraction kit. The total membrane proteins were isolated and digested using procedure outlined before (Prasad et al., 2014) . Triple-quadrupole LC-MS instrument (Xevo TQ-S coupled to ACQUITY UPLC (Waters) was used in ESI positive ionization mode.
This article has not been copyedited and formatted. The final version may differ from this version. Approximately 2 µg of the trypsin digest (5 µL) was injected onto the column (Kinetex 1.7 µm, C18 100A; 100 × 2.1 mm, Phenomenex, Torrance, CA) and eluted at 0.3 mL/min. A mobile phase consisting of water containing 0.1% formic acid (A) and acetonitrile containing 0.1% formic acid (B) was employed. A flow rate of 0.3 mL/min was used with elution starting at 3% B for 3.0 min, followed by a linear gradient increasing to 60% B (3-20.0 min). This was followed by eluting the column with 90% mobile phase B for 0.9 min, and re-equilibrating it at 3%B for 4.9 min. MS/MS analysis was performed by monitoring the surrogate peptide (m/z 602.1 to m/z 673.8, 774.7 and 903.8) and the internal standard (606.2 to 681.7, 911.9 and 783.3) using an optimized fragmentor voltage of 33 V and collision energy of 22 eV. The LC/MS/MS data were processed by integrating the peak areas generated from the reconstructed ion chromatograms for the surrogate peptides and the internal standards using MassLynx 4.1 (Waters). The peak response for two transitions from each peptide were averaged for quantification of samples or standards. Calibrators and quality control samples were assays as before (Prasad et al., 2014) .
Accuracy and precision of the assay was >80% and <20% respectively. OATP1A2 protein expression data (picomoles per milligram) were expressed relative to the total protein content of the isolated membrane, as determined by the BCA assay. All samples were digested and measured in duplicate.
Data Analysis
Three-compartmental model was set up to describe the concentration-dependent and time-course of apical-to-basolateral transcellular transport of rosuvasatin ( Fig. 1) . The differential equations used to describe rate of mass change in apical, cellular and basolateral compartments are as follow:
Where PS influx represents the permeability-surface area product of OATP1A2-mediated influx activity (µL/s); V max represents maximal influx velocity (nmol/min); K m represents the concentration of substrate when the initial transport rate is at one-half of maximum (µM); C A represents apical donor concentration (µM). The models were constructed using SimBiology ® software and the data analysis was conducted in MATLAB (version 8.4, The MathWorks, Inc.).
Assuming initial unidirectional flux into the basolateral compartment (i.e. C B = 0) and rapid equilibration between apical and cellular compartments (dX C /dt = 0), the flux in the apical-tobasolateral direction can be described by following equations:
Substitution of eq. 6 into eq.5 yields the apical-to-basolateral flux equation:
In the absence of OATP1A2 mediated influx clearance (PS influx = 0), apical-to-basolateral flux is given by eq. 8:
Results
Transport of triptan drugs by Oatp1a4
Sumatriptan, naratriptan, and zolmitriptan were administered by continuous infusion up to 60
min to obtain plasma concentrations and brain-and liver-to-plasma ratios between wild-type (WT) and Oatp1a4 knock-out [Oatp1a4 (−/−)] mice. We did not observe any difference in brainand liver-to-plasma ratios between WT and Oatp1a4 (−/−) mice at 60 min. Plasma concentrations at 30 and 60 min were similar between the two genotypes of mice (Fig. 2) . These results indicated that brain and liver penetration of triptans were not impacted by Oatp1a4 in vivo.
To confirm the role Oatp1a4 played in the in vivo studies, uptake was determined in mock and mOatp1a4 transfected HEK293 cells in the absence and presence of rifampicin, a potent inhibitor of mOatp1a4. E 2 17βG and TCA were used as positive controls. The uptake of all test triptans at 10 min was not significantly different between mock and Oatp1a4 transfected HEK293 cells ( 
Tissue distribution of OATP1A2 mRNAs
Human brain OATP1A2 mRNA expression was comparable to BCRP and OATP2B1 and much higher than P-gp (Fig. 5A) . Expression level was also significantly higher in the brain mRNA pools as compared to the other tissues evaluated, including liver, kidney and lung (Fig. 5B) . Fetal brain had much lower OATP1A2 mRNA expression compared with adult human brain (Fig. 5B) .
Expression of OATP1A2 and P-gp in BacMam2-OATP1A2 transduced MDCKII-WT and
MDCKII-MDR1 cells
The mRNA and protein expression of OATP1A2 and mRNA expression of P-gp was characterized in OATP1A2 expressing MDCKII-WT and MDCKII-MDR1 cells. Transduction of BacMam2-OATP1A2 virus in MDCKII-MDR1 cells resulted in a proportional increase in mRNA levels of OATP1A2 with MOI up to 1000, whereas the mRNA level of OATP1A2 increased linearly with MOI up to 500 and then leveled off in MDCKII-WT cells (Fig. 6A ).
mRNA expression of OATP1A2 had a strong correlation with protein levels in combined both types of MDCKII cells (R 2 = 0.74, Fig. 6B ). There was a trend towards human P-gp mRNA level increasing slightly with increasing MOI of BacMam2-OATP1A2 virus in MDCKII-MDR1 (Fig.   6C ). Virus transduction led to a decrease of endogenous canine P-gp in MDCKII-WT cells, whereas it did not affect the expression of canine P-gp in MDCKII-MDR1 cells. MDCKII-WT cells had higher endogenous canine P-gp expression compared to MDCKII-MDR1 cells (Fig.   6D ). Fig. 7A and 7B). Apical-to-basolateral or basolateral-to-apical permeability of the paracellular marker atenolol did not change substantially with MOI of BacMam viruses in MDCKII-WT and MDCKII-MDR1 monolayers ( Fig. 7C and 7D ). We observed a trend of increasing apical-tobasolateral permeability of atenolol with corresponding increases in expression of OATP1A2 in MDCKII-WT cells. However, data variability and lack of correlation between atenolol and lucifer yellow permeability in these wells precluded us to making a definite conclusion. The impact on permeability of zolmitriptan and rosuvastatin was expected to be minimal, since their permeability was at least two-fold higher in the OATP1A2 transfected cells.
Monolayer integrity post BacMam2-OATP1A2 transduction
Transcellular transport of zolmitriptan, rosuvastatin, and fexofenadine across OATP1A2 expressing MDCKII-WT and MDCKII-MDR1 monolayers
Bidirectional transcellular permeability of zolmitriptan, rosuvastatin and fexofenadine was examined in MDCKII-WT and MDCKII-MDR1 monolayers expressing different levels of OATP1A2. Apical-to-basolateral transcellular permeability increased with increasing protein expression level of OATP1A2 in the two types of MDCKII cells (Fig. 8) . The efflux ratio of zolmitriptan and fexofenadine was 7.7 and 3.3 in MDCKII-MDR1 cells, respectively and 1.1 and 3.2 in MDCKII-WT cells, suggesting these are P-gp substrates in line with previous reports (Cvetkovic et al., 1999; Evans et al., 2003 (data not shown here), a non-OATP1A2 substrate that we evaluated previously (Cheng et al., 2012) . OATP1A2 mediated uptake clearance was calculated using eq. 10 for zolmitriptan in MDCKII-WT cells and rosuvastatin in both cell types because their transport was not affected by P-gp in these cells. The uptake clearance was directly proportional to the protein levels of OATP1A2 (Fig. 9) . The coefficient of correlation (R 2 ) was strong for zolmitriptan in MDCKII- 
Kinetic characterization of transcellular transport of Rosuvastatin across OATP1A2 expressing MDCKII-WT monolayers
Rosuvastatin is a BCRP and not a P-gp substrate (Huang et al., 2006) . Since endogenous canine
Bcrp expression was not detectable in our MDCKII cells (data not shown), rosuvastatin was an ideal tool compound to investigate the role of OATP1A2 in transcellular transport in a quantitative manner. To understand more mechanistically the effect of drug concentration on OATP1A2-mediated transcellular transport, apical-to-basolateral permeability of rosuvastatin was examined at concentrations between 0.3 to 300 μM and found to be high and constant at less than 10 µM. Permeability decreased with an increase in concentrations, suggesting saturation of OATP1A2-mediated influx. Permeability decreased in the presence of the OATP1A2 inhibitor, naringin at 500 µM (Fig. 10A) . Transcellular apical-to-basolateral permeability was inhibited ~90% in the presence of naringin at low non-saturable donor concentrations (0.3 and 1 µM). The concentration-dependent apical-to-basolateral permeability of rosuvastatin was fitted using the 3-compartment model described in Fig 1 and correlated well with the observed permeability. The optimized transport kinetic parameters K m , V max and passive permeability were 30.6 µM, 0.02 nmol/min, and 2.2 nm/s, respectively (Fig. 10B) . The resultant OATP1A2-mediated intrinsic transport capacity (V max /K m ) was 10.9 nL/s, which corresponded to 332 nm/s, assuming 0.33 cm 2 of Transwell surface area. The concentration of rosuvastatin over time across MDCKII-WT monolayer expressing the same level of OATP1A2 could be predicted by the three-compartment model using the above-fitted kinetic parameters (Fig. 10C) , further demonstrating the validity of 3-compartment model to quantitatively depict the OATP1A2-mediated transcellular transport of rosuvastatin across the polarized tight barrier.
Discussion
OATP1A2 is highly expressed in the apical membrane of human BBB, suggesting the potential to be targeted for CNS drug delivery. At this time we lack the appropriate in vitro and in vivo tools to investigate the role of this transporter in brain penetration of xenobiotics. We have successfully constructed a versatile in vitro system using the BacMam virus to transiently express OATP1A2 in MDCKII monolayers and used this to examine the effect of OATP1A2 expression and the interplay with P-gp, on transcellular transport of substrate drugs.
OATP1A2 was identified to have high mRNA expression in human brain (Kullak-Ublick et al., 1995) and this finding was later corroborated (Eechoute et al., 2011) . We examined additional transporters in mRNA preparations from whole adult human brains and report comparable OATP1A2 expression relative to BCRP and OATP2B1 and much higher expression than P-gp.
Protein expression of OATP1A2 has been reported in human brain capillaries by immunostaining (Bronger et al., 2005; Gao et al., 2000; Lee et al., 2005) and quantitated in healthy brain tissue by LC-MS/MS at 0.25 fmol/µg protein (Drozdzik et al., 2014) . This is the concentration we achieved in our transduced cell lines, that lead to greatly enhanced transcellular permeability of substrate drugs. The protein expression of OATP1A2 in purified human brain microvessels may be lower than 0.695 fmol/µg protein, as Uchida et al. (2011b) could not detect the protein in purified human brain microvessels by LC-MS/MS, with this sensitivity limit.
During CNS drug discovery, mouse or rat brains are routinely analyzed to check for penetration of discovery compounds, and along with human P-gp in vitro efflux data, used to make predictions of clinical CNS distribution. P-gp is an important transporter limiting CNS penetration and is similar between the species, unlike the less homologous uptake transporters e.g. OATP1A2 and Oatp1a4 (Feng et al., 2008; Bleasby et al., 2006 (Liu et al., 2014) , with protein levels of 2.11 fmol/µg protein in purified mouse and rat brain microvessels (Kamiie et al., 2008) . The presence of Oatp1a4 at both brain and blood side of rodent BBB could imply a role divergent from the apically expressed OATP1A2 (Bronger et al., 2005; Ose et al., 2010) . As would be expected, OATP1A2 has some overlapping substrate specificity with Oatp1a4 e.g. rocuronium, fexofenadine, estrone-3-sulfate and thyroid hormone (Hagenbuch et al., 2002) . However, OATP1A2 transports compounds, e.g.
deltorphin II and microcystin, that are not substrates of Oatp1a4, while Leu-enkephalin and digoxin are Oatp1a4 specific substrates (Hagenbuch et al., 2002) . We now report additional differences in substrate specificity with triptan drugs. The CNS penetration of systemically administered 14 C-labeled sumatriptan, a relatively hydrophilic triptan, was investigated in mice and only 0.006% of total radioactivity was recovered in the brain (Humphrey et al., 1990) , indicating this drug was not a CNS penetrant. Similarly, sumatriptan was not found in the rat brain in whole body autoradiography studies (Dixon et al., 1993) . However, in a positron emission tomography study in six migraine patients, subcutaneous sumatriptan (6 mg) normalized the migraine attack-related increases in brain serotonin synthesis (Sakai et al., 2008) , demonstrating central efficacy of sumatriptan and potential brain uptake. We found that sumitriptan was an OATP1A2 substrate (Cheng et al., 2012) and this likely contributed to the species difference. Zolmitriptan is another example of a P-gp substrate that is brain penetrable, as evidenced by a clinical PET study with brain-to-blood ratio at ~0.25 (Bergstrom et al., 2006) . We found this to be an OATP1A2 substrate as well (Cheng et al., 2012 OATP1A2 is an attractive target for enhancing brain penetration because of broad substrate specificity, desirable expression level (at least of mRNA), BBB localization, and our data indicate that this could potentially be leveraged to counteract P-gp efflux. Accurate and robust quantification of the OATP1A2 protein with membrane extracts of highly purified human brain capillaries will help this further. The physiological expression data would help us to contextualize the current in vitro findings as has previously been done for P-gp (Uchida et al., 2011a; Uchida et al., 2014) . The data could also shed light on emerging debate on neuronal (Gao et al., 2014) and more widely accepted brain endothelial localization (Bronger et al., 2005; Gao et al., 2000; Kalvass et al., 2013; Lee et al., 2005 ).
In conclusion, we have successfully constructed OATP1A2 expressing MDCKII monolayers 
